Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-10-03 00:00:00 ET · period of report 2022-09-29 · accession 0001883850-22-000072 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-10-03 | 2022-09-29+ | REGN | Tessier-Lavigne Marc | Dir | S - Sale+OE | $702.24 | -10.8K | 4,084 | -73% | -$7.61M |
| DM | 2022-10-03 | 2022-09-29+ | REGN | Tessier-Lavigne Marc | Dir | M - OptEx | $413.33 | +10.8K | 6,067 | New | +$4.48M |
| DM | 2022-10-03 | 2022-09-29+ | REGN | Tessier-Lavigne Marc | Dir | M - OptEx | $0.00 | -10.8K | 7,040 | -61% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-29 | S | D | 80 | $699.82 | 2,305 | D | — | — | |
| 2 | Common | Common Stock | 2022-09-29 | S | D | 16 | $702.36 | 2,289 | D | — | — | |
| 3 | Common | Common Stock | 2022-09-29 | S | D | 20 | $704.83 | 2,269 | D | — | — | |
| 4 | Common | Common Stock | 2022-09-30 | M | A | 3,428 | $413.33 | 5,697 | D | — | — | |
| 5 | Common | Common Stock | 2022-09-30 | S | D | 3,428 | $698.00 | 2,269 | D | — | — | |
| 6 | Common | Common Stock | 2022-10-03 | M | A | 3,612 | $413.33 | 5,881 | D | — | — | |
| 7 | Common | Common Stock | 2022-10-03 | S | D | 3,612 | $718.00 | 2,269 | D | — | — | |
| 8 | Common | Common Stock | 2022-09-29 | M | A | 3,798 | $413.33 | 6,067 | D | — | — | |
| 9 | Common | Common Stock | 2022-09-29 | S | D | 16 | $686.89 | 6,051 | D | — | — | (F2) Represents volume-weighted average price of sales of 16 shares of Company stock on September 29, 2022 at prices ranging from $686.89 to $686.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 10 | Common | Common Stock | 2022-09-29 | S | D | 321 | $687.90 | 5,730 | D | — | — | (F3) Represents volume-weighted average price of sales of 321 shares of Company stock on September 29, 2022 at prices ranging from $687.05 to $687.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 11 | Common | Common Stock | 2022-09-29 | S | D | 208 | $698.44 | 2,385 | D | — | — | (F10) Represents volume-weighted average price of sales of 208 shares of Company stock on September 29, 2022 at prices ranging from $698.19 to $698.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 12 | Common | Common Stock | 2022-09-29 | S | D | 160 | $697.29 | 2,593 | D | — | — | (F9) Represents volume-weighted average price of sales of 160 shares of Company stock on September 29, 2022 at prices ranging from $697.10 to $697.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 13 | Common | Common Stock | 2022-09-29 | S | D | 85 | $696.13 | 2,753 | D | — | — | (F8) Represents volume-weighted average price of sales of 85 shares of Company stock on September 29, 2022 at prices ranging from $696.03 to $696.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 14 | Common | Common Stock | 2022-09-29 | S | D | 554 | $691.59 | 2,838 | D | — | — | (F7) Represents volume-weighted average price of sales of 554 shares of Company stock on September 29, 2022 at prices ranging from $691.29 to $691.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 15 | Common | Common Stock | 2022-09-29 | S | D | 692 | $690.65 | 3,392 | D | — | — | (F6) Represents volume-weighted average price of sales of 692 shares of Company stock on September 29, 2022 at prices ranging from $690.06 to $690.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 16 | Common | Common Stock | 2022-09-29 | S | D | 637 | $688.71 | 5,093 | D | — | — | (F4) Represents volume-weighted average price of sales of 637 shares of Company stock on September 29, 2022 at prices ranging from $688.08 to $688.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 17 | Common | Common Stock | 2022-09-29 | S | D | 1,009 | $689.56 | 4,084 | D | — | — | (F5) Represents volume-weighted average price of sales of 1,009 shares of Company stock on September 29, 2022 at prices ranging from $689.07 to $689.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price. |
| 18 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-10-03 | M | D | 3,612 | $0.00 | 0 | D | $413.33 · — to 2025-01-02 | 3,612 Common Stock | (F11) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
| 19 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-09-30 | M | D | 3,428 | $0.00 | 3,612 | D | $413.33 · — to 2025-01-02 | 3,428 Common Stock | (F11) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |
| 20 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-09-29 | M | D | 3,798 | $0.00 | 7,040 | D | $413.33 · — to 2025-01-02 | 3,798 Common Stock | (F11) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |